COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology
Nicholas J. White, James A Watson, Richard M. Hoglund, Xin Hui S Chan, Phaik Yeong Cheah, Joel Tärning
Abstract
Chloroquine and hydroxychloroquine have been used for over 60 years in the treatment of malaria, amoebic liver abscess, and several rheumatological conditions, but their clinical pharmacology is not well understood. COVID-19 is a new potential indication, although these drugs have only moderate in vitro activity against the SARS-CoV-2 virus and there is no convincing evidence at this time of significant clinical efficacy.
Topics & Concepts
HydroxychloroquineChloroquineContext (archaeology)MedicineCoronavirus disease 2019 (COVID-19)PharmacologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakClinical pharmacologyDrugVirologyMalariaImmunologyInternal medicineBiologyInfectious disease (medical specialty)PaleontologyDiseaseOutbreakDrug-Induced Ocular ToxicityVitamin C and Antioxidants ResearchPharmacological Receptor Mechanisms and Effects